



NEWS RELEASE

Biosensors Completes JWMS Acquisition; Shandong Weigao becomes a Key Shareholder

3 October 2011, Singapore - Biosensors International Group, Ltd. (“**Biosensors**”) and Shandong Weigao Group Medical Polymer Company Limited (“**Shandong Weigao**”) today announced the restructuring of the shareholding in JW Medical Systems Ltd (“**JWMS**”) whereby Biosensors acquired the remaining 50% equity interest in JWMS from Shandong Weigao. Biosensors now owns 100% of JWMS and welcomes Shandong Weigao as one of its key shareholders, with two representatives on its board of directors.

Under the agreement, Shandong Weigao has received from Biosensors: (i) cash payment of S\$160 million (approximately equivalent to US\$122 million based on exchange rate of US\$1:S\$1.3080), (ii) 260 million new ordinary shares, and (iii) US\$120 million aggregate principal amount of 4.0% convertible notes due 2014.

Mr. Yoh-Chie Lu, Chairman of Biosensors said, “We are pleased to have obtained approvals for this deal from the relevant authorities and our shareholders. With JWMS now a fully-owned subsidiary of Biosensors, we are well-positioned to increase our presence in China’s fast-growing drug-eluting stent market. We look forward to working more closely with Shandong Weigao. Together, we will continue to build Biosensors into a world class medical device company.”

“Biosensors has become a leading developer of drug-eluting stents. We intend to actively contribute towards its future growth potential,” said Mr. Chen Xue Li, Chairman of Shandong Weigao. “We are committed to working closely with the management and board of Biosensors to further enhance and unlock the value of the company for its shareholders.”

Biosensors will consolidate JWMS’ operations into its own financial results beginning the second half of its financial year 2012.

Biosensors has released other announcements related to the completion of this acquisition on the SGXNET and also on Biosensors' corporate website at www.biosensors.com under the Investor Relations section.

Shandong Weigao has released the announcement related to the completion of this transaction on the Stock Exchange of Hong Kong Limited at www.hkex.com.hk. It is also available on Shandong Weigao's corporate website at www.weigaogroup.com under the Investor Relations section.

For Biosensors International Group, Ltd

Mr. Wong Teck Yenn
Director, Investor Relations

Tel: (65) 6213 5708
Email: ty.wong@biosensors.com

For Shandong Weigao Group Medical Polymer Company Limited

Ms Phyllis Chan
Head of Business Development and Investor Relations

Tel: (852) 2838 1868
Email: phyllischan@weigao.com.hk

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The forthcoming launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.

About Shandong Weigao Group Medical Polymer Company Limited

Weigao is principally engaged in the research and development, production and sale of single-use medical devices. We offer a wide range of products, including infusion sets, syringes, medical needles, blood bags, blood sampling products; orthopedic materials; blood purification consumables; and stents. We have a nationwide sales network with an extensive customer base of over 5,000 healthcare organizations, including nearly 3,000 hospitals and 400 blood stations.

For more information, please visit www.weigaogroup.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.